Salix, Cedars-Sinai sign license agreement

By Elaine Rigoli

Tampa, Fla., July 5 - Salix Pharmaceuticals, Ltd. has entered into an agreement with Cedars-Sinai Medical Center for the right to use U.S. Patent No. 6,861,053 and U.S. Patent Application No. 11/234,516 relating to methods of diagnosis and treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth.

Under the agreement, Cedars-Sinai grants Salix an exclusive worldwide license related to the use of rifaximin (sold in the United States under the trade name Xifaxan), with a right to sublicense.

Cedars-Sinai also grants Salix a nonexclusive license to use any unpublished research and development information and technical data of Cedars-Sinai as necessary to exploit all rights granted to Salix with respect to rifaximin, with a right to sublicense.

As consideration in the exclusive worldwide license, Salix will pay Cedars-Sinai an undisclosed cash license fee and a royalty stream based upon sales after receipt of Food and Drug Administration approval on the use of Xifaxan as an indication for irritable bowel syndrome.

Salix is a pharmaceutical company located in Raleigh, N.C.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.